---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096649"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:13.251264+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Iterum reports Q2 2024 net loss $5.0M; PDUFA date Oct 25, 2024; AdCom Sept 9

## Summary
- Net loss $5.0M Q2 2024 (vs $12.2M Q2 2023); cash $11.7M; expects runway into 2025 through PDUFA date.
- FDA PDUFA action date October 25, 2024; Advisory Committee meeting September 9, 2024 on stewardship and patient population.
- Closed rights offering August 9, 2024: $7.4M gross ($5.8M net) from 6.1M shares and warrants.
- Received U.S. and Canadian patent allowances for sulopenem combinations expiring 2039-2041.

## SEC filing metadata
- accession: 0000950170-24-096649
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017024096649/0000950170-24-096649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017024096649/itrm-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096649
- JSON: https://secwatch.observer/filing/0000950170-24-096649.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.